Izalontamab Brengitecan
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Izalontamab Brengitecan, covering 2026-02-20 to 2026-04-16. Get the full timeline:
Most recent: Clinical Trial Update: Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) [Phase 2, Phase 3]